☆ 4.7 Meeting Abstract

Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials

JOURNAL OF CLINICAL ONCOLOGY (2008)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 26, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2008.26.15_suppl.4008

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer

Quang Loc Bui, Leo Mas, Antoine Hollebecque, David Tougeron, Christelle de la Fouchardiere, Thomas Pudlarz, Emily Alouani, Rosine Guimbaud, Julien Taieb, Thierry Andre, Raphael Colle, Romain Cohen

Summary: This study retrospectively collected clinical data from 31 patients with dMMR/MSI mCRC. The results showed that there was no improved outcome with CT after ICI failure, but prolonged disease control was observed in some cases.

CANCERS (2022)

Add to Collection

Review Oncology

Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy

Hui Wu, Wenyuan Ma, Congfa Jiang, Ning Li, Xin Xu, Yongfeng Ding, Haiping Jiang

Summary: Gastric cancer is a common and fatal malignant tumor. Microsatellite instability (MSI) has become a major molecular typing approach for gastric cancer, especially in advanced cases. However, its value in resectable gastric cancer is still unclear, and there is no consensus on postoperative adjuvant therapy for MSI-H/dMMR resectable GC patients.

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience

Valentina Tuninetti, Luca Pace, Eleonora Ghisoni, Virginia Quara, Francesca Arezzo, Andrea Palicelli, Vincenzo Dario Mandato, Elena Geuna, Gennaro Cormio, Nicoletta Biglia, Lucia Borsotti, Silvia Gallo, Annamaria Ferrero, Elena Jacomuzzi, Luca Fuso, Jeremy Oscar Smith Pezua Sanjinez, Andrea Puppo, Andrea Caglio, Chiara Rognone, Margherita Turinetto, Giulia Scotto, Massimo Di Maio, Giorgio Valabrega

Summary: Endometrial cancer (EC) is the most common gynecological malignancy, and there has been an increase in incidence and disease-related mortality in recent years. Limited data is available on the response to first-line carboplatin plus paclitaxel in EC. The retrospective RAME study aimed to assess chemotherapy response in MSI-h/dMMR and MSI-l/pMMR EC patients, and found that patients with MSI-l/pMMR had numerically longer PFS and OS compared to MSI-h/dMMR patients in the first-line setting.

CANCERS (2023)

Add to Collection

Article Oncology

Prognostic value of Lynch syndrome, BRAFV600E, and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts

Koen Zwart, Frederieke H. van Der Baan, Romain Cohen, Thomas Aparicio, Christelle de la Fouchardiere, Thierry Lecomte, Cornelis J. A. Punt, David Sefrioui, Rik J. Verheijden, Geraldine R. Vink, G. Emerens Wensink, Aziz Zaanan, Miriam Koopman, David Tougeron, Jeanine M. L. Roodhart

Summary: Current knowledge on prognostic biomarkers in metastatic colorectal cancer (mCRC) is mainly based on mCRC patients with pMMR tumors. It is uncertain whether these biomarkers have the same prognostic value in mCRC patients with dMMR tumors.

CANCER MEDICINE (2023)

Add to Collection

Article Gastroenterology & Hepatology

Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy

Fuxing Zhao, Enxi Li, Guoshuang Shen, Qiuxia Dong, Dengfeng Ren, Miaozhou Wang, Yi Zhao, Zhen Liu, Jinhua Ma, Qiqi Xie, Zhilin Liu, Zitao Li, Lihong Gao, Jiuda Zhao

Summary: This study explored the impact of mismatch repair (MMR) status on survival after 5-FU-based adjuvant chemotherapy in gastric cancer patients. The results showed that patients with mismatch repair defective (dMMR) gastric cancer had better disease-free survival (DFS) than patients with mismatch repair proficient (pMMR) gastric cancer in the surgery alone group, while there was no significant difference in DFS between dMMR and pMMR gastric cancer in the adjuvant chemotherapy group. Among pMMR patients, those receiving adjuvant chemotherapy had better DFS and overall survival (OS) than those receiving surgery alone.

JOURNAL OF GASTROENTEROLOGY (2023)

Add to Collection

Article Oncology

Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods

Chunze Zhang, Yixiang Zhan, Kemin Ni, Zhaoce Liu, Ran Xin, Qiurong Han, Guoxun Li, Hangyu Ping, Yaohong Liu, Xuanzhu Zhao, Wanting Wang, Suying Yan, Jing Sun, Qinghuai Zhang, Guihua Wang, Zili Zhang, Xipeng Zhang, Xia Hu

Summary: The prognostic role of deficient mismatch repair (dMMR) systems in colon cancer patients varies during different postoperative periods. The benefits of dMMR are observed after the first postoperative year. Chemotherapy does not provide significant survival benefits for patients aged ≥75 years.

BMC CANCER (2022)

Add to Collection

Article Oncology

Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

Tong Liu, Shuang Liu, Shangwei Guan, Yu Tai, Yao Jin, Mei Dong

Summary: This study assessed the cost-effectiveness of Pembrolizumab versus chemotherapy for metastatic colorectal cancer patients in China, specifically those with mismatch-repair deficiency or microsatellite instability-high. The results showed that Pembrolizumab had better health outcomes and economic advantages compared to chemotherapy, making it a suitable first-line treatment for mCRC patients in China.

JOURNAL OF CHEMOTHERAPY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Clinical significance of neoadjuvant chemotherapy for locally advanced colorectal cancer patients with deficient mismatch repair: possibly residual value in the era of immunotherapy

Mian Chen, Junguo Chen, Jun Huang, Huashan Liu, Wuteng Cao, Shuangling Luo, Zhanzhen Liu, Huanxin Hu, Sicong Lai, Yujie Hou, Liang Kang, Liang Huang

Summary: This study investigated the tumor response and clinical outcome in locally advanced colorectal cancer (LACC) patients with deficient mismatch repair (dMMR) who received neoadjuvant chemotherapy (NAC). The results showed that NAC was associated with better tumor downstaging and longer 5-year disease-free survival (DFS). Therefore, NAC may be an additional treatment choice for such patients in the future.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)

Add to Collection

Article Oncology

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition

Saori Mishima, Yoichi Naito, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama, Motohiro Kato, Hirotsugu Kenmotsu, Yasuhiro Kodera, Keigo Komine, Takafumi Koyama, Osamu Maeda, Mitsuru Miyachi, Hiroshi Nishihara, Hiroyuki Nishiyama, Shouichi Ohga, Wataru Okamoto, Eiji Oki, Shigeru Ono, Masashi Sanada, Ikuo Sekine, Tadao Takano, Kayoko Tao, Keita Terashima, Katsuya Tsuchihara, Yasushi Yatabe, Takayuki Yoshino, Eishi Baba

Summary: This article summarizes the efficacy of immune checkpoint inhibitors in the treatment of dMMR advanced solid tumors and proposes eight recommendations for proper MMR testing and selection of patients for immunotherapy.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Review Medicine, Research & Experimental

Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France

Montserrat Roset, Mayur Amonkar, Renna Patel, Nuria Lara, Smita Kothari

Summary: This study evaluated real-world treatment patterns and clinical outcomes in patients with dMMR/MSI-H metastatic colorectal cancer (mCRC) and non-CRC receiving standard of care (SOC) regimens. The results showed suboptimal clinical outcomes for patients with dMMR/MSI-H mCRC receiving third-line treatment, indicating a high unmet need that could be addressed with immune checkpoints inhibitors (ICIs).

ADVANCES IN THERAPY (2022)

Add to Collection

Article Pathology

An unusual case of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing

Bogyeong Han, Sehui Kim, Jiwon Koh, Jeong Mo Bae, Hongseok Yun, Yoon Kyung Jeon

Summary: This case report highlights a 90-year-old female with MSI-H/dMMR diffuse large B-cell lymphoma, identified through gene sequencing to confirm the tumor type and further confirm microsatellite instability and mismatch repair defect. The study indicates the importance of lymphoma panel sequencing in the diagnosis and treatment of DLBCL.

JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Oncology

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2-Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

Marina Elena Cazzaniga, Claudio Verusio, Mariangela Ciccarese, Alberto Fumagalli, Donata Sartori, Maria Rosaria Valerio, Mario Airoldi, Gabriella Moretti, Corrado Ficorella, Lorenzo Gianni, Andrea Michelotti, Alberto Zambelli, Antonio Febbraro, Daniele Generali, Mirco Pistelli, Ornella Garrone, Antonino Musolino, Patrizia Vici, Michela Maur, Lucia Mentuccia, Nicla La Verde, Giulia Valeria Bianchi, Salvatore Artale, Livio Blasi, Michelino De Laurentiis, Francesco Atzori, Anna Turletti, Mauro Porpiglia, Daniele Santini, Alessandra Fabi, Vittorio Gebbia, Alessio Schirone, Raffaella Palumbo, Antonella Ferzi, Antonio Frassoldati, Claudio Scavelli, Luca Clivio, Monica Giordano, Michela Donadio, Laura Biganzoli, Lucia Del Mastro, Giancarlo Bisagni, Lorenzo Livi, Clara Natoli, Filippo Montemurro, Ferdinando Riccardi, Emanuela Romagnoli, Paolo Marchetti, Valter Torri, Paolo Pronzato, Giorgio Mustacchi

BREAST CARE (2020)

Add to Collection

Editorial Material Pediatrics

Turn off pain: What has changed 4 years later?

Franca Benini, Irene Terrenato, Pierina Lazzarin, Fabio Borrometi, Momcilo Jankovic, Valter Torri, Luca Giacomelli, Marta Gentili

ACTA PAEDIATRICA (2020)

Add to Collection

Article Oncology

Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study

Diego Cortinovis, Federica Grosso, Luciano Carlucci, Paolo Andrea Zucali, Giulia Pasello, Marcello Tiseo, Francesca Sperandi, Lital Hollander, Francesca Galli, Valter Torri, Eliana Rulli, Stefania Canova, Antonio Maconi, Paolo Bidoli, Giovanni Luca Ceresoli, Maurizio D'Incalci

Summary: The ATREUS study explored the activity and safety of trabectedin in patients with unresectable malignant pleural mesothelioma, finding modest clinical activity in epithelioid patients but with significant liver toxicity. Therefore, further development of this drug in MPM at full doses is not recommended.

CLINICAL LUNG CANCER (2021)

Add to Collection

Article Ophthalmology

Evaluation of a Primary Open-Angle Glaucoma Prediction Model Using Long-term Intraocular Pressure Variability Data A Secondary Analysis of 2 Randomized Clinical Trials

Mae O. Gordon, Feng Gao, Julia Beiser Huecker, J. Philip Miller, Mathew Margolis, Michael A. Kass, Stefano Miglior, Valter Torri

JAMA OPHTHALMOLOGY (2020)

Add to Collection

Article Oncology

Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system

Arsela Prelaj, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Mavis Mensah, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla, Riccardo Lobefaro, Benedetta Trevisan, Francesco Trovo, Valter Torri, Gabriella Sozzi, Marina Chiara Garassino, Mattia Boeri

TRANSLATIONAL LUNG CANCER RESEARCH (2020)

Add to Collection

Article Oncology

LKB1mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial

Claudio Vernieri, Monica Ganzinelli, Eliana Rulli, Gabriella Farina, Anna Cecilia Bettini, Claudia Bareggi, Lorenzo Rosso, Diego Signorelli, Giulia Galli, Giuseppe Lo Russo, Claudia Proto, Massimo Moro, Stefano Indraccolo, Adele Busico, Gabriella Sozzi, Valter Torri, Mirko Marabese, Broggini Massimo, Marina C. Garassino

ESMO OPEN (2020)

Add to Collection

Article Oncology

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Reid W. Merryman, Luca Castagna, Laura Giordano, Vincent T. Ho, Paolo Corradini, Anna Guidetti, Beatrice Casadei, David A. Bond, Samantha Jaglowski, Michael A. Spinner, Sally Arai, Robert Lowsky, Gunjan L. Shah, Miguel-Angel Perales, Jean Marc Schiano De Colella, Didier Blaise, Alex F. Herrera, Geoffrey Shouse, Chloe Spilleboudt, Stephen M. Ansell, Yago Nieto, Talha Badar, Mehdi Hamadani, Tatyana A. Feldman, Lori Dahncke, Anurag K. Singh, Joseph P. McGuirk, Taiga Nishihori, Julio Chavez, Anthony V. Serritella, Justin Kline, Mohamad Mohty, Remy Dulery, Aspasia Stamatoulas, Roch Houot, Guillaume Manson, Marie-Pierre Moles-Moreau, Corentin Orvain, Kamal Bouabdallah, Dipenkumar Modi, Radhakrishnan Ramchandren, Lazaros Lekakis, Amer Beitinjaneh, Matthew J. Frigault, Yi-Bin Chen, Ryan C. Lynch, Stephen D. Smith, Uttam Rao, Michael Byrne, Jason T. Romancik, Jonathon B. Cohen, Sunita Nathan, Tycel Phillips, Robin M. Joyce, Maryam Rahimian, Asad Bashey, Hatcher J. Ballard, Jakub Svoboda, Valter Torri, Martina Sollini, Chiara De Philippis, Massimo Magagnoli, Armando Santoro, Philippe Armand, Pier Luigi Zinzani, Carmelo Carlo-Stella

Summary: Anti-PD-1 monoclonal antibodies have shown high response rates in classic Hodgkin lymphoma patients, but relapse is common. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade carries increased toxicity, with post-transplant cyclophosphamide (PTCy) prophylaxis showing significant improvements in progression-free survival (PFS) and graft-versus-host disease (GVHD)-free survival (GRFS).

LEUKEMIA (2021)

Add to Collection

Article Oncology

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

Arsela Prelaj, Achille Bottiglieri, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla, Riccardo Lobefaro, Federico Nichetti, Sara Manglaviti, Mario Occhipinti, Alice Labianca, Monica Ganzinelli, Rosaria Gallucci, Nicoletta Zilembo, Gabriella Francesca Greco, Valter Torri, Filippo de Braud, Marina C. Garassino

Summary: This study investigated the use of Poziotinib in patients with EGFR/HER2 exon 20 insertion mutation metastatic non-small-cell lung cancer, showing a median progression-free survival of 5.6 months and a median overall survival of 9.5 months. The overall response rate was 30% and the disease control rate was 80%. Main toxicities included skin rash and diarrhea.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic value of CT integrated with clinical and laboratory data during the first peak of the COVID-19 pandemic in Northern Italy: A nomogram to predict unfavorable outcome

Enzo Angeli, Serena Dalto, Stefano Marchese, Lucia Setti, Manuela Bonacina, Francesca Galli, Eliana Rulli, Valter Torri, Cinzia Monti, Roberta Meroni, Giordano Domenico Beretta, Massimo Castoldi, Emilio Bombardieri

Summary: This study evaluated the prognostic role of chest CT in COVID-19 patients during the first peak of the pandemic, finding that visual analysis of CT provides useful information for prognostic evaluations and its predictive value is increased by evaluating CT in combination with clinical and laboratory data.

EUROPEAN JOURNAL OF RADIOLOGY (2021)

Add to Collection

Article Immunology

Heme catabolism by tumor-associated macrophages controls metastasis formation

Francesca Maria Consonni, Augusto Bleve, Maria Grazia Totaro, Mariangela Storto, Paolo Kunderfranco, Alberto Termanini, Fabio Pasqualini, Chiara Ali, Chiara Pandolfo, Francesco Sgambelluri, Giulia Grazia, Mario Santinami, Andrea Maurichi, Massimo Milione, Marco Erreni, Andrea Doni, Marco Fabbri, Laura Gribaldo, Eliana Rulli, Miguel Parreira Soares, Valter Torri, Roberta Mortarini, Andrea Anichini, Antonio Sica

Summary: This study identifies a distinct subset of TAMs with high rates of heme catabolism by HO-1, playing a critical role in shaping a prometastatic tumor microenvironment and favoring immunosuppression, angiogenesis and epithelial-to-mesenchymal transition. These TAMs originate from BM precursors, accumulate in the blood of tumor bearers, and preferentially localize at the invasive margin through Nrf2 activation and NF-kappa B1-CSF1R-C3aR axis coordination. Hindering their recruitment or deletion of HO-1 inhibits metastasis formation and enhances anticancer immunotherapy, making them a potential antimetastatic target and prognostic blood marker.

NATURE IMMUNOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy

Maria Teresa Sandri, Elena Azzolini, Valter Torri, Sara Carloni, Chiara Pozzi, Michela Salvatici, Michele Tedeschi, Massimo Castoldi, Alberto Mantovani, Maria Rescigno

Summary: The frequency of IgG positivity and SARS-CoV-2 infection in Lombardy is dependent on the geographical exposure to the virus, primarily due to family interactions rather than hospital exposure. While females had a higher IgG positivity rate than males, the level of antibodies was similar. Smoking was associated with a lower IgG positivity rate, but did not affect IgG plasma levels.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Medicine, General & Internal

Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how

Anders Kehlet Norskov, Theis Lange, Emil Eik Nielsen, Christian Gluud, Per Winkel, Jan Beyersmann, Jacobo de Una-Alvarez, Valter Torri, Laurent Billot, Hein Putter, Jorn Wetterslev, Lehana Thabane, Janus Christian Jakobsen

Summary: Trialists often fail to report if or how underlying statistical assumptions were validated when analysing and presenting results of randomised clinical trials, which may lead to biased trial results. A lack of consensus on how to assess and report underlying assumptions in the existing literature prompted the development of suggestions to guide trialists in testing and validating these assumptions. Collaborative efforts between statisticians and trialists from different research centres resulted in detailed recommendations on assessing and addressing violations of underlying statistical assumptions to improve the validity of randomised clinical trial results.

BMJ EVIDENCE-BASED MEDICINE (2021)

Add to Collection

Meeting Abstract Oncology

International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

S. Novello, V. Monica, M. Serke, C. Grohe, A. Meyer, M. Geissler, I. Colantonio, E. Stoelben, F. Cecere, W. Schutte, C. Schumann, G. Valmadre, G. Borra, M. Schena, A. Morabito, A. Santo, R. Chiari, V. Gregorc, M. Reck, C. Manegold, F. Griesinger, A. Follador, A. Ferrari, A. Bearz, O. Caffo, N. Dickgreber, L. Irtelli, G. H. Wiest, H. Sotoparra, M. Spatafora, L. Righi, V. Torri, L. Porcu, F. Arizio, G. Scagliotti

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT)

J. Whisenant, S. Wong, V. Torri, J. Revuelta, B. Halmos, G. Ceresoli, I. Monnet, S. Popat, O. Arrieta, M. Azab, A. Dingemans, J. Spasic, J. Van Meerbeeck, G. Recondo, N. Reinmuth, A. Valter, M. Unk, R. Ghalehtaki, D. Steinfort, J. Chorostowska-Wynimko, L. Viola, L. Horn, S. Peters, H. A. Wakelee, M. C. Garassino, U. Tapan

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.

Alberto F. Sobrero, Thierry Andre, Jeffrey A. Meyerhardt, Axel Grothey, Timothy Iveson, Takayuki Yoshino, Ioannis Sougklakos, Jeffrey P. Meyers, Roberto Labianca, Mark P. Saunders, Dewi Vernerey, Takeharu Yamanaka, Ioannis Boukovinas, Eiji Oki, Vassilis Georgoulias, Valter Torri, Andrea Harkin, Julien Taieb, Anthony Frank Shields, Qian Shi

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.